Frequency of Hepatitis B Virus Screening in Patients with Systemic Lupus Erythematosus

Basit Öğe Kaydı
dc.contributor.authorCabalak, Mehmet
dc.contributor.authorKimyon, Gezmis
dc.contributor.authorBal, Tayibe
dc.date.accessioned2024-09-18T20:59:15Z
dc.date.available2024-09-18T20:59:15Z
dc.date.issued2020
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractIntroduction: Immunosuppressive drug use is common in the treatment of systemic lupus erythematosus (SLE). In cases receiving immunosuppressive therapy, screening for hepatitis B reactivation risk is also recommended. In this study, we aimed to investigate the frequency of hepatitis B screening in cases diagnosed as having SLE, who were followed up in the Rheumatology Clinic of Hatay Mustafa Kemal University. Materials and Methods: We included 93 patients who were followed-up in the Rheumatology Clinic of Hatay Mustafa Kemal University with the diagnosis of SLE between July 2017-December 2019 in our study. The screening rates of hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core protein antibody (anti-HBc IgG) of the cases and the immunosuppressive drugs used by them were analyzed retrospectively. Results: The mean age of the cases was 38 years (minimum-maximum: 18-79), and 91.4% were women. Of the cases, 43 (46.2%) were determined to be never screened for hepatitis B, 34 (36.6%) screened inadequately, and only 16 (17.2%) screened fully. In 22 cases receiving high-risk immunosuppressive therapy, the rate of full screening of hepatitis B was 27.3%. Conclusion: In patients with SLE, even those who used high-risk immunosuppressive therapy, screening rates were found low. We think that awareness should be increased in this regard by performing joint training with clinics that start immunosuppressive therapy, a periodic repetition of these trainings should be done, and also multi-center studies should be conducted.en_US
dc.identifier.doi10.4274/mjima.galenos.2020.2020.8
dc.identifier.issn2147-673X
dc.identifier.scopus2-s2.0-85111614663en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.urihttps://doi.org/10.4274/mjima.galenos.2020.2020.8
dc.identifier.urihttps://hdl.handle.net/20.500.12483/12476
dc.identifier.volume9en_US
dc.identifier.wosWOS:000591513500008en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofMediterranean Journal of Infection Microbes and Antimicrobialsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSystemic lupus erythematosusen_US
dc.subjecthepatitis B screeningen_US
dc.subjectimmunosuppressive therapyen_US
dc.titleFrequency of Hepatitis B Virus Screening in Patients with Systemic Lupus Erythematosusen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
220.63 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu